These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 9614876)

  • 1. Immunization with a recombinant envelope protein (rgp90) of EIAV produces a spectrum of vaccine efficacy ranging from lack of clinical disease to severe enhancement.
    Raabe ML; Issel CJ; Cook SJ; Cook RF; Woodson B; Montelaro RC
    Virology; 1998 May; 245(1):151-62. PubMed ID: 9614876
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro antibody-dependent enhancement assays are insensitive indicators of in vivo vaccine enhancement of equine infectious anemia virus.
    Raabe ML; Issel CJ; Montelaro RC
    Virology; 1999 Jul; 259(2):416-27. PubMed ID: 10388665
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhancement of EIAV replication and disease by immunization with a baculovirus-expressed recombinant envelope surface glycoprotein.
    Wang SZ; Rushlow KE; Issel CJ; Cook RF; Cook SJ; Raabe ML; Chong YH; Costa L; Montelaro RC
    Virology; 1994 Feb; 199(1):247-51. PubMed ID: 8116252
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of antibody parameters as potential correlates of protection or enhancement by experimental vaccines to equine infectious anemia virus.
    Hammond SA; Raabe ML; Issel CJ; Montelaro RC
    Virology; 1999 Sep; 262(2):416-30. PubMed ID: 10502520
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A particulate viral protein vaccine reduces viral load and delays progression to disease in immunized ponies challenged with equine infectious anemia virus.
    Hammond SA; Cook SJ; Falo LD; Issel CJ; Montelaro RC
    Virology; 1999 Feb; 254(1):37-49. PubMed ID: 9927572
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vivo evolution of the gp90 gene and consistently low plasma viral load during transient immune suppression demonstrate the safety of an attenuated equine infectious anemia virus (EIAV) vaccine.
    Ma J; Jiang C; Lin Y; Wang X; Zhao L; Xiang W; Shao Y; Shen R; Kong X; Zhou J
    Arch Virol; 2009; 154(5):867-73. PubMed ID: 19363668
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic immunization with codon-optimized equine infectious anemia virus (EIAV) surface unit (SU) envelope protein gene sequences stimulates immune responses in ponies.
    Cook RF; Cook SJ; Bolin PS; Howe LJ; Zhou W; Montelaro RC; Issel CJ
    Vet Microbiol; 2005 Jun; 108(1-2):23-37. PubMed ID: 15885929
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of inactivated whole-virus and subunit vaccines in preventing infection and disease caused by equine infectious anemia virus.
    Issel CJ; Horohov DW; Lea DF; Adams WV; Hagius SD; McManus JM; Allison AC; Montelaro RC
    J Virol; 1992 Jun; 66(6):3398-408. PubMed ID: 1316455
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Expression and immunogenicity of equine infectious anemia virus membrane protein GP90].
    Dai CB; Xiao Y; Lu H; Shen RX; Shao YM
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2003 Mar; 17(1):73-6. PubMed ID: 12870025
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Equine Infectious Anemia Virus (EIAV): what has HIV's country cousin got to tell us?
    Leroux C; Cadoré JL; Montelaro RC
    Vet Res; 2004; 35(4):485-512. PubMed ID: 15236678
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A live attenuated equine infectious anemia virus proviral vaccine with a modified S2 gene provides protection from detectable infection by intravenous virulent virus challenge of experimentally inoculated horses.
    Li F; Craigo JK; Howe L; Steckbeck JD; Cook S; Issel C; Montelaro RC
    J Virol; 2003 Jul; 77(13):7244-53. PubMed ID: 12805423
    [TBL] [Abstract][Full Text] [Related]  

  • 12. C-terminal truncation of the transmembrane protein of an attenuated lentiviral vaccine alters its in vitro but not in vivo replication and weakens its potential pathogenicity.
    Jiang CG; Gao X; Ma J; Lin YZ; Wang XF; Zhao LP; Hua YP; Liu D; Zhou JH
    Virus Res; 2011 Jun; 158(1-2):235-45. PubMed ID: 21539871
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An attenuated EIAV vaccine strain induces significantly different immune responses from its pathogenic parental strain although with similar in vivo replication pattern.
    Lin YZ; Shen RX; Zhu ZY; Deng XL; Cao XZ; Wang XF; Ma J; Jiang CG; Zhao LP; Lv XL; Shao YM; Zhou JH
    Antiviral Res; 2011 Nov; 92(2):292-304. PubMed ID: 21893100
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of a canarypox-vectored recombinant vaccine expressing the hemagglutinin gene of equine influenza H3N8 virus in the protection of ponies from viral challenge.
    Minke JM; Toulemonde CE; Coupier H; Guigal PM; Dinic S; Sindle T; Jessett D; Black L; Bublot M; Pardo MC; Audonnet JC
    Am J Vet Res; 2007 Feb; 68(2):213-9. PubMed ID: 17269889
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fine specificity of equine infectious anaemia virus gp90-specific antibodies associated with protective and enhancing immune responses in experimentally infected and immunized ponies.
    Grund CH; Lechman ER; Pezzuolo NA; Issel CJ; Montelaro RC
    J Gen Virol; 1996 Mar; 77 ( Pt 3)():435-42. PubMed ID: 8601778
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune responses and viral replication in long-term inapparent carrier ponies inoculated with equine infectious anemia virus.
    Hammond SA; Li F; McKeon BM; Cook SJ; Issel CJ; Montelaro RC
    J Virol; 2000 Jul; 74(13):5968-81. PubMed ID: 10846078
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A pilot study on an attenuated Chinese EIAV vaccine inducing broadly neutralizing antibodies.
    Meng Q; Lin Y; Ma J; Ma Y; Zhao L; Li S; Liang H; Zhou J; Shen R; Zhang X; Shao Y
    Arch Virol; 2011 Aug; 156(8):1455-62. PubMed ID: 21499906
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Control of equine infectious anemia virus is not dependent on ADCC mediating antibodies.
    Tschetter JR; Byrne KM; Perryman LE; McGuire TC
    Virology; 1997 Apr; 230(2):275-80. PubMed ID: 9143283
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transient immune suppression of inapparent carriers infected with a principal neutralizing domain-deficient equine infectious anaemia virus induces neutralizing antibodies and lowers steady-state virus replication.
    Craigo JK; Leroux C; Howe L; Steckbeck JD; Cook SJ; Issel CJ; Montelaro RC
    J Gen Virol; 2002 Jun; 83(Pt 6):1353-1359. PubMed ID: 12029150
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recombinant envelope protein (rgp90) ELISA for equine infectious anemia virus provides comparable results to the agar gel immunodiffusion.
    Reis JK; Diniz RS; Haddad JP; Ferraz IB; Carvalho AF; Kroon EG; Ferreira PC; Leite RC
    J Virol Methods; 2012 Mar; 180(1-2):62-7. PubMed ID: 22227617
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.